# Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT

> **NCT03395860** · PHASE2 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 100 (estimated)

## Conditions studied

- Graft-versus-host-disease
- Prophylaxis

## Interventions

- **DRUG:** ATG

## Key facts

- **NCT ID:** NCT03395860
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-30
- **Primary completion:** 2020-05-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395860, "Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03395860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*